September 11, 2025 C-Path Concludes 2025 Global Impact Conference with Progress Across Rare Diseases, Neurology and Pediatrics Global regulators, industry leaders, scientists, and patient advocates set near-term commitments on early interception...
September 10, 2025 C-Path’s Global Impact Conference | Every Stage, Every Step: Transforming Lives Through Optimized Drug Development | Day 2 Recap Day 2 of the C-Path Global Impact Conference built on the momentum of opening day...
September 9, 2025 C-Path’s Global Impact Conference | Every Stage, Every Step: Transforming Lives Through Optimized Drug Development | Day 1 Recap Day 1 of Critical Path Institute's Global Impact Conference, #CGIC2025, opened with powerful conversations on accelerating...
September 7, 2025 World Duchenne Awareness Day: Celebrating 10 Years of D-RSC’s Commitment to Serve the Duchenne Community Today is the World Duchenne Awareness Day (WDAD), an annual event that raises global awareness and understanding of Duchenne...
September 8, 2025 C-Path Welcomes Rare Disease Advocacy Leader Ronald J. Bartek to Board of Directors C-Path today announced the election of Ronald J. Bartek to its Board of Directors.
December 15, 2025-December 16, 2025 Complex in Vitro Model Qualification Framework Public Workshop #3 C-Path's Predictive Safety Testing consortium (PSTC) is proud to announce the third public workshop on evidentiary...
September 4, 2025 C-Path’s Translational Therapeutics Accelerator Marks Record Year with Seven BRIDGe Awards Advancing Potential Therapies Across Cancer, Infectious Disease, Neurology and Immunology Program launched in 2022 has grown into a global pipeline partner for academic teams, awarding approximately $2.48 million in 2025
September 4, 2025 From Data to Hope: C-Path’s Polycystic Kidney Disease Outcomes Consortium and the Power of Data Sharing Every year on September 4, families, patients, advocates, and researchers come together to recognize Polycystic Kidney Disease...
September 8, 2025 Shaping the Future of AATD: Patient Perspectives to Drive the Next Decade of Innovation in Alpha-1 Antitrypsin Deficiency On September 8, C-Path and the Alpha-1 Foundation are co-hosting a virtual workshop, Shaping the Future of AATD: Patient...
August 21, 2025 HDYO Joins C-Path’s Huntington’s Disease Consortium to Amplify Youth Voices in Drug Development TUCSON, Ariz., August 21, 2025 — Critical Path Institute’s® (C-Path) Huntington’s Disease Regulatory Science Consortium (HD